Bard Announces Second Quarter Results

C. R. Bard, Inc. (NYSE:BCR) today reported 2014 second quarter financial results. Second quarter 2014 net sales were $827.1 million, an increase of 9 percent over the prior-year period on a reported basis. Excluding the impact of foreign exchange, second quarter 2014 net sales increased 8 percent over the prior-year period.

For the second quarter 2014, net sales in the U.S. were $555.1 million, an increase of 12 percent over the prior-year period. Net sales outside the U.S. were $272.0 million, an increase of 4 percent over the prior-year period on a reported basis. Excluding the impact of foreign exchange, second quarter 2014 net sales outside the U.S. increased 2 percent over the prior-year period.

For the second quarter 2014, net loss was ($119.4 million) and diluted loss per share was ($1.59), reflecting a net charge for estimated costs related to product liability matters. Adjusting for this charge and other items that affect the comparability of results between periods, second quarter 2014 net income was $143.0 million and diluted earnings per share, after adjusting for certain items that affect comparability between periods and excluding amortization of intangibles, was $2.06, an increase of 22 percent and 30 percent, respectively, as compared to second quarter 2013 results.

Timothy M. Ring, chairman and chief executive officer, commented, “Once again we exceeded our expectations for revenue growth this quarter. We continue to believe that executing our investment plan will accelerate the sustainable growth rate of the overall portfolio and put us in a position to provide revenue growth in the mid-to-high single digits with attractive returns for shareholders.”

C. R. Bard, Inc. (www.crbard.com), headquartered in Murray Hill, NJ, is a leading multinational developer, manufacturer and marketer of innovative, life-enhancing medical technologies in the fields of vascular, urology, oncology and surgical specialty products.

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current expectations, the accuracy of which is necessarily subject to risks and uncertainties. These statements are not historical in nature and use words such as “anticipate”, “estimate”, “expect”, “project”, “intend”, “forecast”, “plan”, “believe”, and other words of similar meaning in connection with any discussion of future operating or financial performance. Many factors may cause actual results to differ materially from anticipated results including product developments, sales efforts, income tax matters, the outcomes of contingencies such as legal proceedings, and other economic, business, competitive and regulatory factors. The company undertakes no obligation to update its forward-looking statements. Please refer to the Cautionary Statement Regarding Forward-Looking Information in our March 31, 2014 Form 10-Q for more detailed information about these and other factors that may cause actual results to differ materially from those expressed or implied.

Notes to Non-GAAP Reconciliation of (Loss) Earnings

• For the second quarter 2014, the following items affected the comparability of results between periods: (i) charges of $22.5 million pre-tax for acquisition-related items including transaction costs, purchase accounting adjustments and integration costs; and (ii) charges of $262.7 million pre-tax related to estimated costs for product liability matters, net of recoveries, which includes $4.2 million of litigation-related defense costs in connection with the District Court’s order that the company prepare 200 individual cases for trial (the “WHP Pre-Trial Order”). The net effect of these items increased net loss by $262.4 million, or $3.37 diluted loss per share available to common shareholders. Amortization of intangible assets was $26.6 million pre-tax, which decreased net income on an adjusted basis by $17.7 million, or $0.23 diluted earnings per share available to common shareholders.
• For the second quarter 2013, the following items affected the comparability of results between periods: (i) charges of $1.9 million pre-tax for acquisition-related items including purchased research and development, transaction costs and purchase accounting adjustments; (ii) a charge of $3.2 million pre-tax related to an asset impairment; (iii) a reversal of $1.4 million pre-tax of restructuring costs; and (iv) charges of $292.4 million pre-tax related to estimated costs for product liability matters, net of recoveries, and other litigation matters. The net effect of these items increased net loss by $278.8 million, or $3.37 diluted loss per share available to common shareholders. Amortization of intangible assets was $21.4 million pre-tax, which decreased net income on an adjusted basis by $14.5 million, or $0.18 diluted earnings per share available to common shareholders.
• For the six months ended June 30, 2014, the following items affected the comparability of results between periods: (i) charges of $25.6 million pre-tax for acquisition-related items including transaction costs, purchase accounting adjustments and integration costs; (ii) charges of $262.7 million pre-tax related to estimated costs for product liability matters, net of recoveries, which includes $4.2 million of litigation-related defense costs in connection with the WHP Pre-Trial Order; (iii) a gain of $7.1 million pre-tax related to the sale of an equity investment; and (iv) a decrease of $10.9 million in the income tax provision associated with the completion of IRS examinations for the tax years 2008 through 2010. The net effect of these items decreased net income by $248.9 million, or $3.16 diluted earnings per share available to common shareholders. Amortization of intangible assets was $53.2 million pre-tax, which decreased net income on an adjusted basis by $35.4 million, or $0.45 diluted earnings per share available to common shareholders.
• For the six months ended June 30, 2013, the following items affected the comparability of results between periods: (i) charges of $2.6 million pre-tax for acquisition-related items including purchased research and development, transaction costs, purchase accounting adjustments and integration costs; (ii) charges of $8.9 million pre-tax related to asset impairments; (iii) reversal of $1.4 million pre-tax of restructuring costs; and (iv) charges of $318.2 million pre-tax related to estimated costs for product liability matters, net of recoveries, and other litigation matters. The net effect of these items increased net loss by $308.8 million, or $3.70 diluted loss per share available to common shareholders. Amortization of intangible assets was $43.0 million pre-tax, which decreased net income on an adjusted basis by $29.1 million, or $0.35 diluted earnings per share available to common shareholders.

This press release contains financial measures that are not calculated in accordance with United States generally accepted accounting principles (GAAP). These non-GAAP measures are reconciled to their most directly comparable GAAP measures in the above tables.

This press release includes net sales excluding the impact of foreign exchange. The company analyzes net sales on a constant currency basis to better measure the comparability of results between periods. Because changes in foreign currency exchange rates have a non-operating impact on net sales, the company believes that evaluating growth in net sales on a constant currency basis provides an additional and meaningful assessment of net sales to both management and the company’s investors.

In addition, this press release includes the following non-GAAP measures: (1) cost of goods sold excluding charges for acquisition-related items and asset impairments; (2) marketing, selling and administrative expense excluding charges for acquisition-related items; (3) research and development expense excluding charges for acquisition-related items; (4) other (income) expense, net, excluding acquisition-related items, litigation charges, net of recoveries, which includes litigation-related defense costs in connection with the WHP Pre-Trial Order, gain on sale of investment, asset impairments, and a reversal of restructuring costs; (5) income tax provision excluding a decrease associated with the completion of IRS examinations and the tax effect of the items set forth in (1) through (4) above; (6) net income excluding the items set forth in (1) through (5) above; and (7) diluted earnings per share available to common shareholders excluding the items set forth in (1) through (5) above and amortization of intangible assets.

The company excluded the items described above because they may cause certain statements of operations categories not to be indicative of ongoing operating results, and therefore affect the comparability of results between periods. The company therefore believes that these non-GAAP measures provide an additional and meaningful assessment of the company’s ongoing operating performance. Because the company has historically reported non-GAAP results to the investment community, management also believes that the inclusion of these non-GAAP measures provides consistency in its financial reporting and facilitates investors’ understanding of the company’s historic operating trends by providing an additional basis for comparisons to prior periods. Management uses these non-GAAP measures: (1) to establish financial and operational goals; (2) to monitor the company’s actual performance in relation to its business plan and operating budgets; (3) to evaluate the company’s core operating performance and understand key trends within the business; and (4) as part of several components it considers in determining incentive compensation.

Management recognizes that the use of these non-GAAP measures has limitations, including the fact that they may not be comparable with similar non-GAAP measures used by other companies and that management must exercise judgment in determining which types of charges or other items should be excluded from the non-GAAP information. Management compensates for these limitations by providing full disclosure of each non-GAAP measure and a reconciliation to the most directly comparable GAAP measure. All non-GAAP measures are intended to supplement the applicable GAAP disclosures and should not be considered in isolation from, or as a replacement for, financial information prepared in accordance with GAAP. For a reconciliation of these non-GAAP measures to the most comparable GAAP measures, please see the above tables.